J & J Will Acquire Alios BioPharma For a Whopping $1.75 billion

By:
 
Sept. 30, 2014 - PRLog -- Johnson & Johnson  joins the list of major pharmaceutical giants acquiring smaller biotech/biopharma firms encompassing a growing trend of big pharma’s initiative to further research and development of specific drugs to treat rare diseases and cultivate therapies in areas of unmet medical need. The company has announced their plans to acquire Alios Biopharma, a clinical stage biopharmaceutical company based in San Francisco, California for $1.75 billion in cash. Alios BioPharma’s current pipeline includes therapies in development to treat viral infections including respiratory syncytial virus (RSV), influenza, rhinovirus, and coronavirus.diseases. The company’s lead compound AL-8176, is an orally administered anti viral therapy currently undergoing Phase II studies to treat infants with respiratory syncytial virus (RSV).

“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, M.D., Ph.D., Global Head, Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson. “AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”

Pending clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, the transaction is expected to close by the fourth quarter of 2014.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

With this acquisition, the development of potential antiviral therapeutics will certainly be a critical boon to J & J’s current pipeline. This will without a doubt bolster the need for both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they prefer individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.

Contact
NAPSRx
***@napsronline.org
1-800-284-1060
End
Source: » Follow
Email:***@napsronline.org Email Verified
Tags:Napsrx, Napsr, CNPR Certification Program, Pharmaceutical Sales Training, Sales Marketing
Industry:Biotech, Health
Location:Texas - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
NAPSRx News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share